Patents Assigned to Nucleix Ltd.
  • Patent number: 11952632
    Abstract: Methods and kits for detection of cancer-related mutations in a DNA sample using enzymatic restriction and real-time PCR. A DNA sample is subjected to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA, followed by co-amplification of a restriction locus comprising a cancer mutation site and a control locus. A ratio of signal intensities of the amplification products of the restriction locus and the control locus is used to detect the cancer-related mutation.
    Type: Grant
    Filed: January 6, 2019
    Date of Patent: April 9, 2024
    Assignee: NUCLEIX LTD.
    Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh
  • Publication number: 20240093302
    Abstract: Methods and systems for assessing the presence of cancer in a subject and predicting the tissue source of the cancer are provided, by analyzing DNA methylation markers in cell- free DNA samples, particularly cell-free DNA from plasma samples.
    Type: Application
    Filed: January 18, 2022
    Publication date: March 21, 2024
    Applicant: NUCLEIX LTD.
    Inventors: Danny FRUMKIN, Adam WASSERSTROM, Revital KNIRSH
  • Publication number: 20240026453
    Abstract: Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high-throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 25, 2024
    Applicant: NUCLEIX LTD.
    Inventors: Danny FRUMKIN, Adam WASSERSTROM, Nimrod AXELRAD, Revital KNIRSH
  • Patent number: 11866786
    Abstract: Methods and kits for identification of lung cancer in a subject based on alterations in DNA methylation at selected genomic loci are provided.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: January 9, 2024
    Assignee: NUCLEIX LTD.
    Inventors: Danny Frumkin, Adam Wasserstrom
  • Publication number: 20240002923
    Abstract: Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.
    Type: Application
    Filed: April 17, 2023
    Publication date: January 4, 2024
    Applicant: NUCLEIX LTD.
    Inventors: Danny FRUMKIN, Adam WASSERSTROM, Revital KNIRSH
  • Publication number: 20230220458
    Abstract: Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
    Type: Application
    Filed: September 5, 2022
    Publication date: July 13, 2023
    Applicant: NUCLEIX LTD.
    Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh, Orna Savin
  • Patent number: 11629375
    Abstract: Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: April 18, 2023
    Assignee: NUCLEIX LTD.
    Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh
  • Patent number: 11434528
    Abstract: Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: September 6, 2022
    Assignee: NUCLEIX LTD.
    Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh, Orna Savin
  • Patent number: 9476100
    Abstract: Methods and kits for identification of bladder cancer in a subject based on alterations in DNA methylation at selected genomic loci are provided.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: October 25, 2016
    Assignee: Nucleix Ltd.
    Inventors: Danny Frumkin, Adam Wasserstrom